37 related articles for article (PubMed ID: 38748758)
1. Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray.
Saito N; Matsuo T; Tsuda H; Yokota H; Okada H
PLoS One; 2024; 19(5):e0303614. PubMed ID: 38748758
[TBL] [Abstract][Full Text] [Related]
2. Pathological identification of HER2-low breast cancer: Tips, tricks, and troubleshooting for the optimal test.
Sajjadi E; Guerini-Rocco E; De Camilli E; Pala O; Mazzarol G; Venetis K; Ivanova M; Fusco N
Front Mol Biosci; 2023; 10():1176309. PubMed ID: 37077201
[TBL] [Abstract][Full Text] [Related]
3. Improving HER2 testing reproducibility in HER2-low breast cancer.
Sajjadi E; Venetis K; Ivanova M; Fusco N
Cancer Drug Resist; 2022; 5(4):882-888. PubMed ID: 36627898
[TBL] [Abstract][Full Text] [Related]
4. Current Biological, Pathological and Clinical Landscape of HER2-Low Breast Cancer.
Zhang H; Peng Y
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612123
[TBL] [Abstract][Full Text] [Related]
5. Selecting patients with HER2-low breast cancer: Getting out of the tangle.
Baez-Navarro X; Salgado R; Denkert C; Lennerz JK; Penault-Llorca F; Viale G; Bartlett JMS; van Deurzen CHM
Eur J Cancer; 2022 Nov; 175():187-192. PubMed ID: 36137393
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
[TBL] [Abstract][Full Text] [Related]
7. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.
Moutafi M; Robbins CJ; Yaghoobi V; Fernandez AI; Martinez-Morilla S; Xirou V; Bai Y; Song Y; Gaule P; Krueger J; Bloom K; Hill S; Liebler DC; Fulton R; Rimm DL
Lab Invest; 2022 Oct; 102(10):1101-1108. PubMed ID: 35595825
[TBL] [Abstract][Full Text] [Related]
8. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.
Venetis K; Crimini E; Sajjadi E; Corti C; Guerini-Rocco E; Viale G; Curigliano G; Criscitiello C; Fusco N
Front Mol Biosci; 2022; 9():834651. PubMed ID: 35372498
[TBL] [Abstract][Full Text] [Related]
9. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.
Fernandez AI; Liu M; Bellizzi A; Brock J; Fadare O; Hanley K; Harigopal M; Jorns JM; Kuba MG; Ly A; Podoll M; Rabe K; Sanders MA; Singh K; Snir OL; Soong TR; Wei S; Wen H; Wong S; Yoon E; Pusztai L; Reisenbichler E; Rimm DL
JAMA Oncol; 2022 Apr; 8(4):1-4. PubMed ID: 35113160
[TBL] [Abstract][Full Text] [Related]
10. HER2-Low Breast Cancers.
Zhang H; Katerji H; Turner BM; Hicks DG
Am J Clin Pathol; 2022 Mar; 157(3):328-336. PubMed ID: 34519765
[TBL] [Abstract][Full Text] [Related]
11. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
12. Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis.
Suzuki M; Yagishita S; Sugihara K; Ogitani Y; Nishikawa T; Ohuchi M; Teishikata T; Jikoh T; Yatabe Y; Yonemori K; Tamura K; Hasegawa K; Hamada A
Clin Cancer Res; 2021 Jul; 27(14):3970-3979. PubMed ID: 33980613
[TBL] [Abstract][Full Text] [Related]
13. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Sung H; Ferlay J; Siegel RL; Laversanne M; Soerjomataram I; Jemal A; Bray F
CA Cancer J Clin; 2021 May; 71(3):209-249. PubMed ID: 33538338
[TBL] [Abstract][Full Text] [Related]
14. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
Taube JM; Akturk G; Angelo M; Engle EL; Gnjatic S; Greenbaum S; Greenwald NF; Hedvat CV; Hollmann TJ; Juco J; Parra ER; Rebelatto MC; Rimm DL; Rodriguez-Canales J; Schalper KA; Stack EC; Ferreira CS; Korski K; Lako A; Rodig SJ; Schenck E; Steele KE; Surace MJ; Tetzlaff MT; von Loga K; Wistuba II; Bifulco CB;
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414858
[TBL] [Abstract][Full Text] [Related]
15. New Technologies to Image Tumors.
McNamara G; Lucas J; Beeler JF; Basavanhally A; Lee G; Hedvat CV; Baxi VA; Locke D; Borowsky A; Levenson R
Cancer Treat Res; 2020; 180():51-94. PubMed ID: 32215866
[TBL] [Abstract][Full Text] [Related]
16. Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond.
Marchiò C; Annaratone L; Marques A; Casorzo L; Berrino E; Sapino A
Semin Cancer Biol; 2021 Jul; 72():123-135. PubMed ID: 32112814
[TBL] [Abstract][Full Text] [Related]
17. Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
Li AC; Zhao J; Zhao C; Ma Z; Hartage R; Zhang Y; Li X; Parwani AV
Breast Cancer Res Treat; 2020 Apr; 180(2):321-329. PubMed ID: 32002765
[TBL] [Abstract][Full Text] [Related]
18. Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR
Guo Z; Tada H; Kitamura N; Hamada Y; Miyashita M; Harada-Shoji N; Sato A; Hamanaka Y; Tsuboi K; Harada N; Takano-Kasuya M; Okada H; Nakano Y; Ohuchi N; Hayashi SI; Ishida T; Gonda K
Cancers (Basel); 2019 Apr; 11(4):. PubMed ID: 31013810
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
